This clinical trial is focused on studying the effects of a new treatment for people with birch pollen-induced allergic rhinitis or rhinoconjunctivitis. These conditions are common allergies that cause symptoms like sneezing, runny nose, and itchy eyes during the birch pollen season. The treatment being tested is a vaccine called mannan-conjugated allergoid (polymerized) Betula pendula parenteral vaccine, which is given as an injection under the skin. The study will compare this vaccine to a placebo, which looks the same but does not contain the active ingredients.
The purpose of the study is to assess how well the vaccine works in reducing allergy symptoms in adolescents and adults who suffer from these conditions. Participants will receive the vaccine or placebo through injections over a period of time. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual vaccine or the placebo, to ensure unbiased results.
Throughout the study, participants will be monitored to see how their symptoms change during the peak birch pollen season. The main goal is to determine if the vaccine can effectively reduce the symptoms and the need for other allergy medications. This research could lead to a new way to manage birch pollen allergies and improve the quality of life for those affected by these seasonal conditions.
Germany 
Poland 
